Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

432.07 +9.75 (+2.31%)

Streaming Delayed Price Updated: 10:25 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

68 69 Next >

3 Monster Stocks to Buy Without Any Hesitation ↗

December 27, 2023

These are easy choices for investors seeking market-beating long-term gains.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 25, 2023

Via Benzinga

3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗

December 25, 2023

These are ideal stocks to buy sooner rather than later.

Via The Motley Fool

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗

December 23, 2023

Editas isn't out of the woods yet, but it's better off than before.

Via The Motley Fool

1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗

December 23, 2023

The stock has been in the news lately.

Via The Motley Fool

Market Whales and Their Recent Bets on VRTX Options ↗

December 22, 2023

Via Benzinga

How Is The Market Feeling About Vertex Pharmaceuticals? ↗

December 21, 2023

Via Benzinga

$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

December 19, 2023

Via Benzinga

After This Landmark Win, Is CRISPR Therapeutics a Buy? ↗

December 15, 2023

CRISPR Therapeutics stock already has advanced in the double digits this year.

Via The Motley Fool

5 Top Stocks to Buy With Your End-of-the-Year Bonus ↗

December 23, 2023

Your bonus could become the gift that keeps on giving.

Via The Motley Fool

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗

December 22, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Via The Motley Fool

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗

December 22, 2023

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Via The Motley Fool

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗

December 21, 2023

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

Via InvestorPlace

Should you consider NASDAQ:VRTX for quality investing? ↗

December 21, 2023

Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.

Via Chartmill

Is Vertex Pharmaceuticals Sitting on a Gold Mine? ↗

December 21, 2023

Vertex shares have climbed about 40% this year.

Via The Motley Fool

Why Vertex Stock Is Soaring Today ↗

December 13, 2023

The drugmaker's non-opioid painkiller is showing promise in a select set of patients.

Via The Motley Fool

CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief ↗

December 20, 2023

The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.

Via InvestorPlace

Better Growth Stock: Archer Aviation or Prime Medicine? ↗

December 19, 2023

Which of these innovation-themed growth stocks is the better buy?

Via The Motley Fool

Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

December 18, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Stocks Profiting From Unstoppable Trends That Could Make You Rich ↗

December 18, 2023

It's important to choose companies involved in trends that have long-term potential.

Via The Motley Fool

CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall? ↗

December 16, 2023

The benefits from its first drug launch will trickle in slowly, at least at first.

Via The Motley Fool

Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip ↗

December 16, 2023

This biotech could have more winners on the way.

Via The Motley Fool

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Via InvestorPlace

Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review ↗

December 15, 2023

The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests.

Via Investor's Business Daily

Topics Economy Stocks

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

December 15, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

3 Small-Cap Stocks That Could Skyrocket 1000% by 2030 ↗

December 14, 2023

With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy.

Via InvestorPlace

Topics ETFs

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024 ↗

December 13, 2023

These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.

Via InvestorPlace

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 13, 2023

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700...

Via Benzinga

Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday? ↗

December 13, 2023

Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates.

Via Benzinga

Topics Economy

Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial ↗

December 13, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.